As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

HexemBio emerges with a breakthrough blood stem cell rejuvenation technology led by Draper Associates and an advisory ...

A burgeoning field is launching its first clinical trial to find out whether dialling back cell development can safely ...

HexemBio has launched with a seed round led by Draper Associates to advance a blood stem cell rejuvenation therapy backed by Robert Langer.

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

Mineral casts of cancer cell surfaces reprogram fat cells into stem cells and improve insulin sensitivity in obese mice ...

A mature cell of one type can be turned into a mature cell of another type without the cell having to pass through an earlier stage of development. This is called direct reprogramming, a reliable but ...

Advances in iPSC technology and in vivo reprogramming are expanding the possibilities for cell therapy. Explore the science ...

Researchers have defined a new genetic disease caused by a mutation in the IVNS1ABP gene. The condition marks a rare ...

This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American NEW YORK—Despite a cloud of regulatory ...

Aside from reprogramming and transdifferentiation, the longer-existing approach to generating neurons and NSCs has been differentiating them from pluripotent cells, initially from embryonic stem cells ...